Abstract
The current article describes a 72-year-old woman who suffered an acute myocardial
infarction due to plaque erosion (PE) 2 weeks after abemaciclib treatment onset due
to advanced breast cancer. Abemaciclib is a cyclin-dependent kinase 4 and 6 inhibitor
that has recently demonstrated efficacy and safety in advanced breast cancer. Of major
concern, however, reported thromboembolic rates in randomized clinical trials testing
this drug range from 0.6 to 5%. To the best of our knowledge this is the first thrombotic
coronary side effect ever reported. We suggest that a treatment that increases thromboembolic
risk, such abemaciclib, may have triggered PE in our patient, 15 days after abemaciclib
initiation. New molecules are promising in cancer treatment; however, care must be
paid to their potential cardiotoxic effects.
Keywords
thrombosis - acute myocardial infarction - cardiology
